Hierarchical Diagnosis for Adult Diffuse Glioma Based on Deep Learning

Study Overview
=================
Brief Summary
-----------------
This is a restrospective study to establish a deep learning model based on multi-parametric magnetic resonance imaging scans to predict Grade, histopathologic type and genotype of adult diffuse Glioma.

Detailed Description
-----------------
Glioma is a common kind of tumor in central nervous system. The pre-operative prediction of grade, histopathologic type and genotype is important for treatment and management of Adult diffuse Glioma patients. Right now, most of the diagnostic prediction models on glioma are based on 2016 WHO central nervous system tumor guideline. The goal of this study is to establish a new deep learning model to predict Grade, histopathologic type and genotype of adult diffuse Glioma. We will recruit 500 patients with pathologically confirmed diagnosis of Glioblastoma, Astrocytoma and Oligodendroglioma who received neurologic surgery in our center. Each subject underwent pre-operative multi-parametric magnetic resonance imaging scans including T1WI, T2WI, T1CE, FLAIR and DWI. Pathologic diagnosis of each patient are available in pathology department. A deep learning based hierarchical diagnosis

Official Title
-----------------
Artificial Intelligence Research of Hierarchical Diagnosis for Adult Diffuse Glioma Based on Deep Learning

Conditions
-----------------
Astrocytoma, Glioblastoma Multiforme, Oligodendroglioma

Intervention / Treatment
-----------------
* Diagnostic Test: multi-parametric magnetic resonance imaging scan
* Diagnostic Test: Pathology examination


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients undergoing surgery in Nanjing DrumTower Hospital between 2010.01 and 2022.05 with post-surgery pathological diagnosis of WHO Grade II to IV Adult Diffuse Glioma. Available pre-surgery T1WI, T2WI, T1CE, FLARI and DWI MR sequences No pre-surgery anti-tumor therapy Exclusion Criteria: Poor image quality Failed image preprocessing Unavailable pathology data

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Glioblastoma Group<br>Patients with the diagnosis of Glioblastoma based on 2021 WHO central nervous system tumor guideline. | Diagnostic Test: multi-parametric magnetic resonance imaging scan<br>* Pre-operative multi-parametric magnetic resonance imaging scans including T1WI, T2WI, T1CE, FLAIR and DWI were taken for clinical needs.<br>Diagnostic Test: Pathology examination<br>* The tumor specimen obtained from the surgery were sent to the pathology department for histopathologic examination, immunohistochemistry and gene sequencing test<br>|
| Astrocytoma Group<br>Patients with the diagnosis of Astrocytoma based on 2021 WHO central nervous system tumor guideline. | Diagnostic Test: multi-parametric magnetic resonance imaging scan<br>* Pre-operative multi-parametric magnetic resonance imaging scans including T1WI, T2WI, T1CE, FLAIR and DWI were taken for clinical needs.<br>Diagnostic Test: Pathology examination<br>* The tumor specimen obtained from the surgery were sent to the pathology department for histopathologic examination, immunohistochemistry and gene sequencing test<br>|
| Oligodendroglioma Group<br>Patients with the diagnosis of Oligodengroglioma based on 2021 WHO central nervous system tumor guideline. | Diagnostic Test: multi-parametric magnetic resonance imaging scan<br>* Pre-operative multi-parametric magnetic resonance imaging scans including T1WI, T2WI, T1CE, FLAIR and DWI were taken for clinical needs.<br>Diagnostic Test: Pathology examination<br>* The tumor specimen obtained from the surgery were sent to the pathology department for histopathologic examination, immunohistochemistry and gene sequencing test<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Tumor Grade | Tumor Grade based on 2021 WHO central nervous system tumor guideline | up to 2 weeks | 
| Tumor Histologic diagnosis | Tumor histologic diagnosis based on 2021 WHO central nervous system tumor guideline | up to 2 weeks | 
| Tumor genotype | Tumor genotype based on 2021 WHO central nervous system tumor guideline | up to 2 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Astrocytoma, Glioblastoma, Oligodendroglioma, deep learning, artificial intelligence